• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does Exposure to Aspirin During Pregnancy Impact Blood Pressure in Offspring – a 7 Year Follow Up Study

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Chen et al. (BJOG, 2018) sought to determine whether maternal aspirin use during pregnancy is associated with childhood blood pressure

METHODS:

  • Secondary analysis of the Collaborative Perinatal Project
    • Prospective cohort study of singleton births
    • Maternal and child health data | 12 US academic medical centers (1959 – 1976)
    • Exposure: Within 4 weeks before LMP | During pregnancy
  • Primary outcome: Offspring blood pressure at age 7 years
  • Data on covariates that could impart bias were also collected (including pregnancy outcomes such as SGA)
  • Linear and multivariate logistic regression analysis was used to draw associations

RESULTS:

  • 15,793 women were exposed to aspirin
  • In utero aspirin exposure demonstrated the following offspring BP associations at 7 years of age
    • High systolic blood pressure (SBP):  Risk reduction of 11% (95% CI, 0.85– 0.93)
    • High diastolic blood pressure (DBP): Risk reduction of 20% (95% CI, 0.76–0.84)
    • Mean decrease of 0.62 mmHg for SBP and 1.04 mmHg for DBP at 7 years of age
  • Compared with children born to mothers without aspirin exposure, those whose mothers were exposed to aspirin for at least 7 days during pregnancy had approximately
    • 10% reduced risk of high SBP
    • 27% reduced risk of high DBP
    • Mean reduction of 0.61 and 1.27 mmHg in SBP and DBP at 7 years of age
    • Risk reduction appears to be independent of maternal hypertensive disorders
  • The earlier the aspirin exposure occurred during pregnancy, the lower the risk of elevated childhood high blood pressure
    • Dose-response effect seen based on number of days of exposure
    • Risk reduction effect was consistent across all trimesters

CONCLUSION:

  • Limitations of this study include
    • Lack of dosage information (and may likely be typical therapeutic and not low dose, based years of the original study)
    • Lack of indications for aspirin use
  • Study strengths include large cohort size and multiple data points with 7 year follow up of offspring  
  • In utero exposure to aspirin decreased risk of high childhood blood pressure
  • More traditional risk factors for cardiovascular risks such as BMI were not as strongly associated with elevated BP, suggesting that aspirin may exert independent effects on placental vascularization or epigenetic mechanisms

Learn More – Primary Sources:

Association of intrauterine exposure to aspirin and blood pressure at 7 years of age: a secondary analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Aspirin Treatment for Women at Risk for Preeclampsia – ACOG and USPSTF Recommendations  
ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia
Does Low Dose Aspirin Reduce the Risk of Spontaneous Preterm Birth?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site